Treatment of Patients With Takayasu Arteritis Complicated With Pulmonary Artery Involvement

Sponsor
Chinese Pulmonary Vascular Disease Research Group (Other)
Overall Status
Recruiting
CT.gov ID
NCT05388682
Collaborator
(none)
200
1
347.4
0.6

Study Details

Study Description

Brief Summary

evaluate the effect of medical treatment and percutaneous transluminal pulmonary angioplasty on takayasu arteritis with pulmonary artery involvement

Condition or Disease Intervention/Treatment Phase
  • Device: Percutaneous transluminal pulmonary angioplasty

Study Design

Study Type:
Observational
Anticipated Enrollment :
200 participants
Observational Model:
Cohort
Time Perspective:
Prospective
Official Title:
Observation of Long Term Effect of Medical and PTPA Treatment on Patients With Takayasu Arteritis Complicated With Pulmonary Artery Involvement
Actual Study Start Date :
Jan 19, 2014
Anticipated Primary Completion Date :
Dec 31, 2042
Anticipated Study Completion Date :
Dec 31, 2042

Outcome Measures

Primary Outcome Measures

  1. all cause death [2014/1/1-2042/12/31]

    all cause death

  2. mean pulmonary arterial pressure change [2014/1/1-2042/12/31]

    change of mean pulmonary arterial pressure after treatment

  3. pulmonary vascular resistance change [2014/1/1-2042/12/31]

    chagne of pulmonary vascular resistance after treatment

  4. 6MWD change [2014/1/1-2042/12/31]

    change of six minute walk distance after treatment

  5. peak VO2 change [2014/1/1-2042/12/31]

    change of peak oxygen consumption after treatment

  6. NT-proBNP change [2014/1/1-2042/12/31]

    change of NT-proBNP after treatment

  7. RV/LV change [2014/1/1-2042/12/31]

    change of right ventricular end-diastolic diameter versus laboratory left ventricular end-diastolic diameterafter treatment

  8. CI change [2014/1/1-2042/12/31]

    change of cardiac index after treatment

Eligibility Criteria

Criteria

Ages Eligible for Study:
N/A and Older
Sexes Eligible for Study:
All
Accepts Healthy Volunteers:
No
Inclusion Criteria:
  • patients diagnosed with Takayasu arteries with pulmonary arteries involvement
Exclusion Criteria:
  • Patients had pulmonary artery stenosis arising from CTEPH, fibrosing mediastinitis and congenital pulmonary artery stenosis

Contacts and Locations

Locations

Site City State Country Postal Code
1 uwai Hospital, National Center for Cardiovascular Diseases, Chinese Academy of Medical Sciences and Peking Union Medical College Beijing China 100000

Sponsors and Collaborators

  • Chinese Pulmonary Vascular Disease Research Group

Investigators

  • Principal Investigator: zhihong Liu, doctor, Fuwai Hospital, National Center for Cardiovascular Diseases, Chinese Academy of Medical Sciences and Peking Union Medical College

Study Documents (Full-Text)

None provided.

More Information

Publications

None provided.
Responsible Party:
Chinese Pulmonary Vascular Disease Research Group
ClinicalTrials.gov Identifier:
NCT05388682
Other Study ID Numbers:
  • TAPAI
First Posted:
May 24, 2022
Last Update Posted:
May 24, 2022
Last Verified:
May 1, 2022
Individual Participant Data (IPD) Sharing Statement:
No
Plan to Share IPD:
No
Studies a U.S. FDA-regulated Drug Product:
No
Studies a U.S. FDA-regulated Device Product:
No
Keywords provided by Chinese Pulmonary Vascular Disease Research Group
Additional relevant MeSH terms:

Study Results

No Results Posted as of May 24, 2022